Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Balance Sheet: Assets

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: assets

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash and cash equivalents 7.69 6.59 8.25 10.63 11.35
Marketable securities 13.53 17.28 24.53 15.87 11.04
Accounts receivable, net 14.16 16.45 17.13 18.24 23.73
Inventories 7.89 8.18 7.80 8.22 7.67
Prepaid expenses and other current assets 1.17 0.92 1.17 1.41 1.31
Current assets 44.43% 49.42% 58.88% 54.37% 55.10%
Marketable securities 25.30 23.57 16.31 22.56 26.88
Property, plant, and equipment, net 12.62 12.18 12.53 12.88 13.69
Intangible assets, net 3.10 3.04 3.14 3.13 0.03
Deferred tax assets 10.05 8.78 7.79 5.90 3.45
Other noncurrent assets 4.49 3.01 1.34 1.15 0.85
Noncurrent assets 55.57% 50.58% 41.12% 45.63% 44.90%
Total assets 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

The asset composition of the entity demonstrates notable shifts over the five-year period. Current assets initially represent a majority of total assets, but this proportion decreases over time, while the share of noncurrent assets increases. Within current assets, a significant dynamic is observed in the allocation between cash, marketable securities, and accounts receivable.

Liquidity Position
The percentage of total assets held as cash and cash equivalents exhibits a consistent decline from 11.35% in 2021 to 6.59% in 2024, before a slight recovery to 7.69% in 2025. Simultaneously, marketable securities experience a more volatile pattern, increasing substantially from 11.04% in 2021 to a peak of 24.53% in 2023, then decreasing to 13.53% in 2025. This suggests a strategic shift in liquidity management, potentially involving the conversion of cash into marketable securities and then a partial reversal of this trend. Accounts receivable, net, shows a steady decrease from 23.73% to 14.16% over the period, indicating improved efficiency in collecting receivables or a change in sales terms.
Long-Term Investments & Fixed Assets
The proportion of total assets allocated to property, plant, and equipment, net, remains relatively stable, fluctuating between 12.18% and 13.69% throughout the period. However, intangible assets, net, experience a significant increase from 0.03% in 2021 to 3.10% in 2025, suggesting increased investment in intellectual property or other intangible resources. Deferred tax assets also demonstrate a consistent upward trend, rising from 3.45% to 10.05%, potentially reflecting changes in tax planning strategies or accumulated tax benefits. Other noncurrent assets show the most substantial relative growth, increasing from 0.85% to 4.49%, indicating expanding long-term investments beyond the traditionally categorized assets.
Overall Asset Structure
The balance between current and noncurrent assets shifts considerably. In 2021 and 2022, current assets comprise over half of total assets. However, by 2025, noncurrent assets represent 55.57% of the total, surpassing current assets which fall to 44.43%. This indicates a move towards a more long-term focused asset base. The combined percentage of marketable securities, both current and noncurrent, is substantial, representing approximately 30.81% of total assets in 2025, highlighting the importance of investment holdings to the entity’s overall financial position.

These changes in asset allocation suggest a dynamic financial strategy, potentially driven by evolving business needs, investment opportunities, and tax considerations. The increasing proportion of noncurrent assets indicates a long-term investment horizon and a potential shift in the entity’s operational focus.

AI Ask an analyst for more